A detailed history of Vontobel Holding Ltd. transactions in Trevi Therapeutics, Inc. stock. As of the latest transaction made, Vontobel Holding Ltd. holds 21,859 shares of TRVI stock, worth $247,662. This represents 0.0% of its overall portfolio holdings.

Number of Shares
21,859
Previous 24,900 12.21%
Holding current value
$247,662
Previous $136,000 43.38%
% of portfolio
0.0%
Previous 0.0%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Oct 15, 2025

SELL
$5.62 - $9.62 $17,090 - $29,254
-3,041 Reduced 12.21%
21,859 $195,000
Q2 2025

Jul 23, 2025

SELL
$5.28 - $7.06 $34,103 - $45,600
-6,459 Reduced 20.6%
24,900 $136,000
Q1 2025

Apr 25, 2025

BUY
$3.66 - $6.81 $114,773 - $213,554
31,359 New
31,359 $197,000

Others Institutions Holding TRVI

About Trevi Therapeutics, Inc.


  • Ticker TRVI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 58,322,500
  • Market Cap $661M
  • Description
  • Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritu...
More about TRVI
Track This Portfolio

Track Vontobel Holding Ltd. Portfolio

Follow Vontobel Holding Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vontobel Holding Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Vontobel Holding Ltd. with notifications on news.